Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis

References

• Rothstein B, Gottlieb A. Secukinumab for treating plaque psoriasis. Expert Opinbiolther. 2016;16(1):119–128.
   PubMed Web of Science ®Google Scholar
• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acaddermatol. 2014;70(3):512–516.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Weinstein R, Porter SB, et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537–1541.
   PubMedGoogle Scholar
• Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acaddermatol. 2009;60(2):218–224.
   PubMed Web of Science ®Google Scholar
• Dogra S, Yadav S. Psoriasis in India: prevalence and pattern. Indian J Dermatolvenereolleprol. 2010;76:595–601.
   Web of Science ®Google Scholar
• Singer NG, Fox DA, Haqqi TM, et al. CD6: expression during development, apoptosis and selection of human and mouse thymocytes. IntImmunol. 2002;14:585–597.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res. 2007;299:111–138.
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Euracaddermatolvenereol. 2009;23(Suppl 2):1–70.
   Google Scholar
• Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Dermatol. 2005;153:486–497.
   PubMed Web of Science ®Google Scholar
• Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtschdermatolges. 2007;5:566–574.
   Google Scholar
• Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. Rheumatol Int. 2016;36(5):603–612.
   PubMed Web of Science ®Google Scholar
• Lynch M, Kirby B, Warren RB. Treating moderate to severe psoriasis - best use of biologics. Expert Rev Clinimmunol. 2014;10(2):269–279.
   PubMed Web of Science ®Google Scholar
• Van Cranenburgh OD, De Korte J, Sprangers MA, et al. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol. 2013;169(2):398–405.
   PubMed Web of Science ®Google Scholar
• Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med. 2007;13:242–244.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873.
   PubMed Web of Science ®Google Scholar
• Aira LE, López-Requena A, Fuentes D, et al. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. MAbs. 2014;6(3):783–793.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Torres-Moya R, Reyes G, et al. A clinical exploratory study with itolizumab, an anti-CD6 antibody, in patients with rheumatoid arthritis. Results Immunol. 2012;2:204–211.
   PubMedGoogle Scholar
• Alzumab (Itolizumab) solution for IV infusion [prescribing information]. India: Biocon,Inc; available online http://www.biocon.com/docs/prescribing_information/immunotherapy/Alzumab_pi.pdf. Accessed 05th Sept 2016.
   Google Scholar
• Alonso-Ramirez R, Loisel S, Buors C, et al. Rationale for targeting CD6 as a treatment for autoimmune diseases. Arthritis. 2010;2010:130646.
   PubMedGoogle Scholar
• Gimferrer I, Calvo M, Mittelbrunn M, et al. Relevance of CD 6-mediated interactions in T cell activation and proliferation. J Immunol. 2004;173:2262–2270.
   PubMed Web of Science ®Google Scholar
• Chappell PE, Garner LI, Yan J, et al. Structures of CD6 and its ligand CD166 give insight into their interaction. Structure. 2015;23(8):1426–1436.
   PubMed Web of Science ®Google Scholar
• Nair P, Melarkode R, Rajkumar D, et al. CD6 synergisticco-stimulation promoting proinflammatory response is modulated without tinterferingwith the activated leucocyte cell adhesionmolecule interaction. ClinExpImmunol. 2010;162:116–130.
   Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009 Jul 30;361(5):496–509.
   PubMed Web of Science ®Google Scholar
• Menon R, David BG. Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. ClinCosmetInvestigDermatol. 2015 Apr 17;8:215–222.
   Google Scholar
• Kofler DM, Farkas A, Von Bergwelt-Baildon M, et al. The link between CD6 and autoimmunity: genetic and cellular associations. Curr Drug Targets. 2016;17(6):651–665.
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Reichert JM. 6th Annual European Antibody Congress 2010: november 29–December 1, 2010, Geneva, Switzerland. MAbs. 2011;3(2):111–132.
   PubMedGoogle Scholar
• Anand A, Assudani D, Nair P, et al. Safety, efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque psoriasis – results from a randomized phase II trial. J Immunol. 2010;abstract 184:96–103.
   Web of Science ®Google Scholar
• Krupashankar DS, Dogra S, Kura M, et al. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acaddermatol. 2014;71(3):484–492.
   PubMed Web of Science ®Google Scholar
• Dogra S, Krupashankar DS, Budamakuntla L, et al. Long term efficacy and safety of Itolizumab in patients with moderate to severe chronic plaque psoriasis: a double blind, randomized, withdrawal, placebo controlled study. J Am Acaddermatol. 2015;73(2):331–333.
   PubMed Web of Science ®Google Scholar
• Le Dantec C, Alonso R, Fali T, et al. Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). Immunol Res. 2013;56:341–347.
   PubMed Web of Science ®Google Scholar
• Nott A, Raghavan V, Sashidharan N. Use of itolizumab in chronic plaque psoriasis patients: clinical experience. Ejpmr. 2016;3(3):413–416.
   Google Scholar
• Trasi. S, Sashidharan N. Itolizumab as the first line of treatment in moderate to severe chronic plaque posriasis: A case report. Asian J Pharm Clin Research. 2016;Vol 9Issue(2): 12.
   Google Scholar
• Gupta A, Sharma YK, Deo K, et al. Severe recalcitrant psoriasis treated with itolizumab, a novel anti-CD6 monoclonal antibody. Ijdvl. 2016;82(4):459–461.
   Google Scholar
• Pai GS Itolizumab: a new biologic for management of psoriasis and psoriatic arthritis. Poster no. 065, presented at 4th world psoriasis and psoriatic arthritis conference, July 8-11, 2015, Stockholm Waterfront Congress Center.
   Google Scholar
• Singh V Clinical outcome of a novel anti CD-6 biologic-itolizumab in 7 patients of psoriasis with comorbid conditions. Poster no. 015 presented at 4th world psoriasis and psoriatic arthritis conference, July 8-11, 2015, Stockholm Waterfront Congress Center.
   Google Scholar
• Singh V Anti CD-6 molecule showed promising result in von Zumbusch GPP. Poster no. 062, presented at 4th world psoriasis and psoriatic arthritis conference, July 8-11, 2015, Stockholm Waterfront Congress Center.
   Google Scholar
• Parasramani S Sustained remission achieved with itolizumab in patients with moderate to severe plaque psoriasis-real world experience. Poster no. 068 presented at 4th world psoriasis and psoriatic arthritis conference, July 8-11, 2015, Stockholm Waterfront Congress Center.
   Google Scholar